Holen Sie sich die Stockscreener-App
1.80
0.00%
0.00
Novabridge Biosciences Adr Aktie (NBP) Neueste Nachrichten
symbol__ Stock Quote Price and Forecast - CNN
Novabridge Biosciences ADR (NBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Novabridge Biosciences ADR (NBP) Cash Flow - TradingKey
Novabridge Biosciences ADR (NBP) Institutional Confidence - TradingKey
NBP|Novabridge Biosciences ADR|Price:1.840|Chg%:+0.070 - TradingKey
Novabridge Biosciences ADR (NBP) Balance Sheet - TradingKey
TradingKey - TradingKey
NBP|Novabridge Biosciences ADR|Price:1.790| - TradingKey
Novabridge Biosciences ADR (NBP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Novabridge Biosciences ADR (NBP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Novabridge Biosciences ADR (NBP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Novabridge Biosciences ADR (NBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NBP|Novabridge Biosciences ADR|Price:1.770| - TradingKey
Novabridge Biosciences ADR (NBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026 - GlobeNewswire Inc.
NovaBridge Biosciences SVP sells $3,991 in ordinary shares - Investing.com
Empowering Investor Success - Morningstar
NBPNovaBridge Biosciences ADR Latest SEC Filings - Finviz
NovaBridge appoints Srishti Gupta as new CEO effective July 1 - Investing.com
NovaBridge Biosciences Sponsored ADR Actuals & Estimates (NASDAQ:NBP) - TradingView
Novabridge Biosciences ADR (NBP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Novabridge Biosciences ADR - TradingKey
NovaBridge Biosciences (NBP) corrects major holder stakes in 20-F/A filing - Stock Titan
NovaBridge Biosciences stock surges on FDA Fast Track nod By Investing.com - Investing.com South Africa
NovaBridge Biosciences stock surges on FDA Fast Track nod - Investing.com
Number of shareholders of NovaBridge Biosciences Sponsored ADR – GETTEX:0VY - TradingView
NovaBridge Biosciences SVP Claire Xu sells $13,766 in shares By Investing.com - Investing.com India
NovaBridge Biosciences SVP Claire Xu sells $13,766 in shares - Investing.com
Sean Cao, NovaBridge Biosciences chief BD officer, sells $42,584 in shares - Investing.com
Alpha Buying: Insider Conviction in High-Risk Biotech - Sahm
NovaBridge Biosciences president buys $577,300 in company shares By Investing.com - Investing.com India
NovaBridge Biosciences president buys $577,300 in company shares - Investing.com
NovaBridge appoints Mark Hagler as president, chief commercial officer - Investing.com
NovaBridge Biosciences (NASDAQ: NBP) posts 2025 loss, extends cash runway to 2028 - Stock Titan
H.C. Wainwright reiterates NovaBridge stock rating on FDA feedback - Investing.com India
NovaBridge gets FDA nod for accelerated approval path for givastomig - Investing.com
NovaBridge reports positive Phase 2a data for eye disease drug - Investing.com
NovaBridge enrolls first patient in phase 2 gastric cancer study - Investing.com
NovaBridge Biosciences stock price target raised to $9 by H.C. Wainwright - investing.com
NBP Stock Price and Chart — NASDAQ:NBP - TradingView
NovaBridge chairman to purchase up to $5 million in company shares - Investing.com
NovaBridge stock soars after positive gastric cancer drug results - Investing.com
BTIG Sticks to Their Buy Rating for Ascentage Pharma Group International Unsponsored ADR (AAPG) - The Globe and Mail
What is the current Price Target and Forecast for NovaBridge Biosciences (NBP) - Zacks Investment Research
NovaBridge Biosciences Share Price ADS SPON - Hargreaves Lansdown
NovaBridge Biosciences (0VY.F) stock price, news, quote and history - Yahoo Finance Singapore
What date does NovaBridge Biosciences's (NBP) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
NBP Stock Price | Analyst Target 9.00 & Consensus - eToro
IMAB Stock Price, Quote & Chart | I-MAB-SPONSORED ADR (NASDAQ:IMAB) - ChartMill
I-Mab stock price target raised to $9 from $7 at BTIG on strategic shift - Investing.com
NBP: Transforming into a global biotech, rebranding, and pursuing dual NASDAQ/HKEX listing - TradingView
NBP: Jeva Stomach demonstrates high efficacy and safety, with broad expansion plans and strong financial runway - TradingView
IMAB SEC FilingsI-Mab 10-K, 10-Q, 8-K Forms - Stock Titan
NBP: Reduced net loss and accelerated givastomig progress position I-Mab for key milestones - TradingView
I-Mab (IMAB) Stock Price, News & Analysis - Stock Titan
NBP: Lead asset givastomig shows strong efficacy and safety in gastric cancer, with key data readouts in 2024–2025 - TradingView
NBP: Net loss narrowed to $49.7M as I-Mab pivots to U.S. immuno-oncology focus post-China divestiture - TradingView
NBP: Pipeline advances and solid cash position support I-Mab's clinical and strategic progress - TradingView
Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative
NBP: Uliledlimab, givastomig, and ragistomig advance toward key clinical milestones with strong cash support - TradingView
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):